Harbour BioMed
Harbour BioMed has 1 licensing announcement in this dataset, dated 2025-03-21.
- Country / operating region
- China
- Ticker
- 02142.HK
- Headquarters
- 查無
- Founded
- 查無
- Business
- Biopharmaceutical research and development
- Website
- www.harbourbiomed.com
Pipeline / products
| Asset / platform | Target | Modality | Stage at announcement | Announcement date |
|---|---|---|---|---|
| Harbour Mice antibody programs | 查無 | 查無 | 查無 | 2025-03-21 |
| Asset | Registered / announced phase | Trial | Status | Sponsor | Record date |
|---|---|---|---|---|---|
| Harbour Mice antibody programs | Preclinical (selected programs at announcement) | — | 查無 | 查無 | 2025-03-21 |
Licensing deals
| Date | Counterparty | Asset / platform | Upfront | Near-term | Milestones | Potential total | Other disclosed terms |
|---|---|---|---|---|---|---|---|
| 2025-03-21 | AstraZeneca | Harbour Mice antibody programs | 查無 | 查無 | ≤ USD 4400m | 查無 | Equity USD 105m Combined upfront + near-term + option fees USD 175m The combined amount includes upfront, near-term milestones and option exercise fees; separate components undisclosed. |
| Counterparty | Territory | Royalties |
|---|---|---|
| AstraZeneca | 查無 | Tiered royalties on future net sales. |
Catalysts
查無
Latest monthly revenue
查無
Most advanced drug
查無
Drugnews analysis
查無